Business
Dr Andy Richards Chairs Advisory Panel - New Appts
Dr Andy Richards Chairs Advisory Panel - New Appts.
About this update from Nuformix Plc
[{"type":"text","content":"\n \nRNS Number : 3000Z Nuformix PLC 14 December 2017 \n\n \nNuformix plc\n(\"Nuformix\" or \"the Company\")\n \nAdvisory Panel Appointments\nChaired by Dr Andy Richards\n \nNuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces the following appointments to its Advisory Panel, with immediate effect:\n \nDr Andy Richards CBE - appointed Chairman, Advisory Panel. Andy is Chairman of Congenica, Arecor, and Abcodia, and is a director of Silence Therapeutics plc, Ieso Digital Health, Sensiia, and Cancer Research Technology (commercial arm of CR-UK). He is Chair of the Babraham Research Campus and was until recently a non-executive director of Cambridge University Hospitals Trust.\n \nHis early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience. Since 1999 he has founded, invested in and helped to scale innovative UK based biotechnology and healthcare companies, with more than 25 ventures over the last 16 years. These include companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels, and was awarded a CBE in 2015 for services to life-science investment.\n \nProf Derek Mann - Nuformix has been working with Derek and his team to further validate NFX002, the Nuformix fibrosis programme. Derek will continue to advise the Nuformix team in pre-clinical fibrosis research.\n \nHe is Director of the Newcastle Fibrosis Research Group (NFRG), which is focussed on developing translational solutions to tissue remodelling and scar formation in the liver, lung, kidneys, heart and skin. Derek's research group is primarily interested in understanding the molecular basis for liver fibrosis (scarring) and primary liver cancer. Recent discoveries include mechanisms of transgenerational epigenetic inheritance affecting fibrosis and a role for inflammatory neutrophils in hepatocellular carcinoma. \n \nAt the NFRG he has developed a number of collaborative strategic alliances with major pharmaceutical companies including GSK and Abbvie, which are aimed at translation of the NFRG research to the design of fibrosis biomarkers and new ther...